Breath Biopsy Panel for Respiratory Diseases Now Commercially Available Reports Owlstone Medical
The breath biomarker panel, which is now commercially available, is intended to support research to distinguish between different types of chronic inflammatory airway diseases including asthma, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis, and to facilitate better therapeutic decision making and monitoring.
Owlstone Medical to Join EU-Funded EPHOR Consortium
The consortium aims to further elucidate the complex relationships between environment and disease by developing the concept of the ‘working-life exposome’, which takes into account all occupational and related non-occupational exposures (e.g. lifestyle) throughout the lifespan of an individual.
Owlstone Medical Partners with Thermo Fisher Scientific
The collaboration seeks to advance the application of non-invasive breath sampling to address the challenges of the early detection of disease and the precision medicine delivery of healthcare through the discovery and validation of novel biomarkers
Breath Biopsy Kits Launched by Owlstone Medical
3/28/18: Commercially available research kits extend access to Breath Biopsy technology for discovery of VOC biomarkers in early disease detection and precision medicine
Owlstone Medical and Cancer Research UK (CRUK) Initiate Pan Cancer Clinical Trial to Evaluate Breath Biopsy for Early Detection of Disease
Owlstone Medical, (diagnostics company developing a breathalyzer for disease), today announced the initiation of the PAN Cancer trial for Early Detection of Cancer in Breath. The large scale clinical study will evaluate the use of Owlstone Medical’s...
Owlstone Medical CEO and Breath Biopsy Pioneer Billy Boyle wins Royal Academy of Engineering’s Silver Medal
Billy Boyle, Founder and CEO of Owlstone Medical, (a diagnostics company developing a breathalyzer for disease), is to be awarded the Royal Academy of Engineering’s prestigious Silver Medal. The award recognizes engineer Billy’s work in spearheading the...
Owlstone Medical Establishes Scientific Advisory Board with Appointment of Professor Sir Bruce Ponder
Billy Boyle, co-founder and CEO at Owlstone Medical, commented: “With over four decades’ work in cancer research we are honoured that Professor Sir Bruce Ponder is joining our SAB. His tremendous depth of experience and knowledge will...